Calcineurin inhibitors as neuroprotectants: Focus of tacrolimus and cyclosporin

CNS Drugs

Volumn 13, Issue 1, 2000, Pages 1-13

  Sharkey, John ^a,b   Jones, Paul A ^a   McCarter, Jennifer F ^a   Kelly, John S ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Univ Department of Pharmacology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; TACROLIMUS; UNCLASSIFIED DRUG;

ALLOGRAFT; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL PROLIFERATION; DRUG EFFECT; GERBIL; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION;

EID: 0033956809     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200013010-00001     Document Type: Review

References (207)

1. 1. Bierer BE, Samelson LE, editors. Lymphocyte activation. Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action. Basel: Karger, 1994: 128-55
2. 2. Kunz J, Hall MN. Cyclosporin A, FK506 and rapamycin: more than just immunosuppressants. Trends Biochem Sci 1993; 18 (9): 334-8
3. 3. Liu J. FK506 and cyclosporin: molecular probes for studying intracellular signal transduction. Trends Pharmacol Sci 1993; 14 (5): 182-8
4. 4. Nishiyama M, Izumi S, Okuhara M. Discovery and development of FK506 (Tacrolimus), a potent immunosuppressant of microbial origin. In: Merluzzi VJ, Adams J, editors. The search for anti-inflammatory drugs. Boston (MA): Birkhauser, 1995: 65-104
5. 5. Clipstone NA, Crabtree GR. Identification of calcincurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992; 357 (6380): 695-7
6. 6. Harding MW, Galat A, Uehling DE, et al. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989; 341 (6244): 758-60
7. 7. Siekierka JJ, Hung SHY, Poe M, et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989; 341 (6244): 755-7
8. 8. Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci U S A 1992; 89 (9): 3686-90
9. 9. Liu J, Farmer JD, Lane WS, et al. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 1991; 66 (4): 807-15
10. 10. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 1994; 371 (6495): 336-9
11. 11. Butcher SP, Henshall DC, Teramura Y, et al. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. J Neurosci 1997; 17: 6939-46
12. 12. Sharkey J, Butcher SP. Calcineurin: a target for anti-ischaemic drug therapy [abstract]. J Cereb Blood Flow Metab 1995; 15: S387
13. 13. Sharkey J, Crawford JH, Butcher SP, et al. Tacrolimus (FK506) ameliorates skilled motor deficits produced by middle cerebral artery occlusion in rats. Stroke 1996; 27: 2282-6
14. 14. Aoyama S, Katayama Y, Terashi A. The effect of FK 506, an immunosuppressant, on cerebral infarction volume in focal cerebral ischemia in rats. J Nippon Med Sch 1997; 64 (5): 416-21
15. 15. Shiga Y, Onodera H, Matsuo Y, et al. Cyclosporin-A protects against ischemia-reperfusion injury in the brain. Brain Res 1992; 595 (1): 145-8
16. 16. Bochelen D, Rudin M, Sauter A. Calcineurin inhibitors FK506 and SDZ ASM 981 alleviate the outcome of focal cerebral ischemic/reperfusion injury. J Pharmacol Exp Ther 1999; 288: 653-9
17. 17. Kamiya T, Katayama Y, Aoyama S, et al. Neuroprotective effects of immunosuppressant FK506 in focal cerebral ischemia in the rat-the effect on cerebral infarction, brain edema, immediate early gene and heat shock protein hsp72 [abstract]. J Cereb Blood Flow Metab 1997; 17: S372
18. 18. Kuroda S, Siesjo BK. Postischemic administration of FK506 reduces infarct volume following transient focal brain ischemia. Neurosci Res Com 1996; 19: 83-90
19. 19. Nakai A, Kuroda S, Siesjo BK. Protective effect of FK506 on secondary mitochondrial dysfunction due to transient focal cerebral ischemia in the rat [abstract]. J Cereb Blood Flow Metab 1997; 17: S665
20. 20. Toung TJK, Hurn PD, Bhardwaj A, et al. Immunosuppressive agent FK506 reduces experimental stroke injury [abstract]. J Cereb Blood Flow Metab 1997; 17: S617
21. 21. Drake M, Friberg H, Boris-Moller F, et al. The immunosuppressant FK506 ameliorates ischaemic damage in the rat brain. Acta Physiol Scand 1996; 158 (2): 155-9
22. 22. Folbergrova J, Li PA, Uchino H, et al. Changes in the bioenergetic state of rat hippocampus during 2.5 min of ischemia, and prevention of cell damage by cyclosporin A in hyperglycemic subjects. Exp Brain Res 1997; 114: 44-50
23. 23. Li PA, Uchino H, Elmer E, et al. Amelioration by cyclosporin A of brain damage following 5 or 10 min of ischemia in rats subjected to preischemic hyperglycemia. Brain Res 1997; 753: 133-40
24. 24. Uchino H, Elmer E, Uchino K, et al. Cyclosporin A dramatically ameliorates CAI hippocampal damage following transient forebrain ischaemia in the rat. Acta Physiol Scand 1995; 155: 469-71
25. 25. Wakita H, Tomimoto H, Akiguchi I, et al. Dose-dependent, protective effect of FK506 against white matter changes in the rat brain after chronic cerebral ischemia. Brain Res 1998; 792: 105-13
26. 26. Wakita H, Tomimoto H, Akiguchi I, et al. Protective effect of cyclosporin A on white matter changes in the rat brain after chronic cerebral hypoperfusion. Stroke 1995; 26 (8): 1415-22
27. 27. Ide T, Morikawa E, Kirino T. An immunosuppressant, FK506, protects hippocampal neurons from forebrain ischemia in the Mongolian gerbil. Neurosci Lett 1996; 204: 157-60
28. 28. Hashimoto T, Kawamata T, Tanaka C. Involvement of calcincurin A alpha and A beta in neuronal death in a gerbil model of cerebral ischemia. Nippon Yakurigaku Zasshi 1998; 111: 21-8
29. 29. Katayama Y, Kamiya T, Muramatsu H, et al. Immunosuppressant FK506 enhances immediate early gene expression and prevents delayed neuronal death in the gerbil hippocampus [abstract]. J Cereb Blood Flow Metab 1997; 17: S492
30. 30. Kondo Y, Ogawa N, Asanuma M, et al. Cyclosporin A prevents ischemia-induced reduction of muscarinic acetylcholine receptors with suppression of microglial activation in gerbil hippocampus. Neurosci Res 1995; 22 (1): 123-7
31. 31. Tokime T, Nozaki K, Kikuchi H. Neuroprotective effect of FK506, an immunosuppressant, on transient global ischemia in gerbil. Neurosci Lett 1996; 206: 81-4
32. 32. Yagita Y, Kitagawa K, Matsushita K, et al. Effect of immunosuppressant FK506 on ischemia-induced degeneration of hippocampal neurons in gerbils. Life Sci 1996; 59: 1643-50
33. 33. Ogawa N, Asanuma M, Kondo Y. Involvement of immune mechanism in the progressive brain damage. Jap J Psychopharmacol 1994; 14: 377-81
34. 34. Ogawa N, Tanaka K, Kondo Y, et al. The preventive effect of cyclosporin A, an immunosuppressant, on the late onset reduction of muscarinic acetylcholine receptors in gerbil hippocampus after transient forebrain ischemia. Neurosci Lett 1993; 152 (1-2): 173-6
35. 35. Xu X, Ogata H, Luo XX. Protective effects of cyclosporine and allopurinol on transient global cerebral ischemia in gerbils. J Anesth 1995; 9: 170-5
36. 36. Tanaka K, Fukuuchi Y, Nozaki H, et al. Calcineurin inhibitor, FK506, prevents reduction in the binding capacity of cyclic AMP-dependent protein kinase in ischemic gerbil brain. J Cereb Blood Flow Metab 1997; 17: 412-20
37. 37. Wakabayshi H, Karasawa Y, Tanaka S, et al. The effect of FK506 on warm ischemia and reperfusion injury in the rat liver. Surg Today 1994; 24: 994-1002
38. 38. Dhar DK, Takemoto Y, Nagasue N, et al. FK506 maintains cellular calcium homeostasis in ischemia. Reperfusion injury of the canine liver. J Surg Res 1996; 60: 142-6
39. 39. Dhar DK, Nagasue N, Uchida M, et al. Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. Transplantation 1993; 56: 1555-8
40. 40. Dhar DK, Nagasue N, Kimoto T, et al. The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. Transplantation 1992; 54: 583-8
41. 41. Echevarria MI, GarciaAlonso I, Portugal V, et al. Prevention of ischemic injury in hepatocellular transplantation in the rat [in Spanish]. Rev Esp Enferm Dig 1994; 86 (6): 894-7
42. 42. Garcia-Criado FJ, Palma-Vargas JM, Valdunciel-Garcia JJ, et al. Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. Transplantation 1997; 64: 594-8
43. 43. Garcia-Alonso I, Portugal V, Iturburu I, et al. Modifications induced by cyclosporin A on ischemic liver regeneration. Surg Res Com 1990; 9: 227-33
44. 44. Jin MB, Yamagishi H, Ochiai T, et al. Protective effect of FK 506 on hepatic energy metabolism in warm ischemic canine livers induced by total hepatic vascular exclusion. Transplant Proc 1996; 28: 1108-10
45. 45. Hardy KJ, Tancheroen S, Shulkes A. Premedication with cyclosporine and perindopril modifies the ischaemia-reperfusion injury during liver resection in rats. J Gastro Hepatol 1996; 11: 652-7
46. 46. Kawano K, Bowers JL, Kim YI, et al. FK506 reduces oxidative hepatic injury following cold ischemic preservation and transplantation. Transplant Proc 1996; 28: 1902-3
47. 47. Kawano K, Bowers JL, Clouse ME. Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation. Transplant Proc 1995; 27: 362-3
48. 48. Kawano K, Kim YI, Kai T, et al. Evidence that FK506 alleviates ischemia/reperfusion injury to the rat liver: in vivo demonstration for suppression of TNF-alpha production in response to endotoxemia. Eur Surg Res 1994; 26: 108-15
49. 49. Kawano K, Kim YI, Goto S, et al. A protective effect of FK506 in ischemically injured rat livers. Transplantaion 1991; 52: 143-5
50. 50. Hayashi T, Nagasue N, Kohno H, et al. Beneficial effect of cyclosporine pretreatment in canine liver ischemia. Enzymalic and electronmicroscopic studies. Transplantation 1991; 52: 116-21
51. 51. Hayashi T, Nagasue N, Kohno H, et al. Beneficial effect of cyclosporine pretreatrnent in preventing ischemic damage to the liver in dogs. Transplantation 1988; 46: 923-4
52. 52. Kim YI, Akizuki S, Kawano K, et al. FK 506 prevents critical warm ischemia damage to the pig liver and improves hepatic microcirculation. Transplant Proc 1994; 26: 2384-7
53. 53. Kai T, Kim YI, Kitamura H, et al. Attenuation of cold ischemic liver injury by cyclosporine in association with endotoxemia and chemokine release. Transplant Proc 1994; 26: 2370-4
54. 54. Okano K, Hamamoto I, Izuishi K, et al. Ameliorative effect of FK506 on cold ischemia reperfusion injury of the rat liver. Transplant Proc 1994; 26: 2367-9
55. 55. Kawano K, Kim YI, Ono M, et al. Evidence that both cyclosporin and azathioprine prevent warm ischemia reperfusion injury to the rat liver. Transplant Int 1993; 6: 330-6
56. 56. Kawano K, Kim YI, Kaketani K, et al. The beneficial effect of cyclosporine on liver ischemia in rats. Transplantation 1989; 48; 759-64
57. 57. Sakr MF, McClain CJ, Gavaler JS, et al. FK506 pre-treatment is associated with reduced levels of tumour necrosis factor and interleukin-6 following hepatic ischemia/reperfusion. J Hepatol 1993; 17 (3): 301-7
58. 58. Sakr M, Zetti G, McClain C, et al. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. Transplantation 1992; 53: 987-91
59. 59. Sakr MF, Zetti GM, Farghali H, et al. Protective effect of FK506 against hepatic ischemia in rats. Transplant Proc 1991; 23: 340-1
60. 60. Kim YI, Kawano K, Goto S, et al. Protection of pig liver against normothermic ischemia by immunosuppressants cyclosporine and azathioprine. Transplantation 1992; 54: 182-4
61. 61. Kim YI, Kawano K, Goto S, et al. Amelioration of 3.5-hour warm ischemia time for pig livers by cyclosporine pretherapy, compared with azathioprine. Transplant Proc 1991; 23: 655-6
62. 62. Sawada T, Inoue K, Tanabe T, et al. Prophylactic effect of FK506 on porcine hepatic injury by ischemia [abstract]. Jap J Transplant 1992; 26: S259
63. 63. Konukoglu D, Tasci I, Cetinkale O. Effects of cyclosporin A and ibuprofen on liver ischemia-reperfusion injury in the rat. Clin Chim Acta 1988; 275: 1-8
64. 64. Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, et al. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury: modulating effects of FK506 and cyclosporine. Transplantation 1993; 55: 1265-72
65. 65. Kurokawa T, Kobayashi H, Nonami T, et al. Beneficial effects of cyclosporine on postischemic liver injury in rats. Transplantation 1992; 53: 308-11
66. 66. Wakabayashi H, Karasawa Y, Maeba T, et al. Effect of FK 506 and cyclosporine A on hepatic energy status in the rat after warm ischemia, as monitored by 31P nuclear magnetic resonance spectroscopy in vivo. Transplant Proc 1992; 24: 1993-5
67. 67. Portugal V, Garcia-Alonso I, Barcelo P, et al. Effect of allopurinol, folinic acid, SOD and cyclosporine A on ischemic liver regeneration. Eur Surg Res 1995; 27 (2): 69-76
68. 68. Sakr MF, Abdel-Aal AN. Protective effect of cyclosporine A (CyA) against the hepatic injury associated with ischemia and reperfusion. Int Surg 1996; 81: 180-3
69. 69. Takemoto Y, Dhar DK, Nagasue N, et al. Mechanisms of the protective effect of cyclosporine against hepatic is chemiareperfusion injury in canine model. Surg Res Com 1996; 18: 155-66
70. 70. Tatsuma I, Kim YI, Ono M, et al. Suppression of superoxide production from polymorphonuclear leukocytes by cyclosporine in ischemia-reperfusion of the liver. Transplant Proc 1994; 26: 2413-6
71. 71. Yamanoi A, Nagasue N, Kohno H, et al. Beneficial effect of donor pretreatment with cyclosporin A in porcine liver transplantation. Surg Res Com 1994; 15: 229-36
72. 72. Yamanoi A, Nagasue N, Kohno H, et al. Attenuation of ischemia-reperfusion injury of the liver in dogs by cyclosporine. A comparative study with allopurinol and methylprednisolone. Transplantation 1991; 52: 27-30
73. 73. Morishita K. Protective effect of FK506 on myocardial reperfusion injury following normothermic global ischemia in rat hearts. Sapporo Med J 1996; 65: 113-9
74. 74. Arras M, Strasser R, Mohri M, et al. Tumor necrosis factor-alpha is expressed by monocytes/macrophages following cardiac microembolization and is antagonized by cyclosporine. Basic Res Cardiol 1998; 93: 97-107
75. 75. Nishinaka Y, Sugiyama S, Yokota M, et al. Protective effect of FK506 on ischemia-reperfusion-induced myocardial damage in canine heart. J Cardiovasc Pharmacol 1993; 21 (3): 448-54
76. 76. Arteaga D, Odor A, Lopez RM, et al. Impairment by cyclosporin A of reperfusion-induced arrhythmias. Life Sci 1992; 51: 1127-34
77. 77. Gatewood LB, Larson DF, Bowers MC, et al. A novel mechanism for cyclosporine: inhibition of myocardial ischemia and reperfusion injury in a heterotopic rabbit heart transplant model. J Heart Lung Transplant 1996; 15: 936-47
78. 78. Griffiths EJ, Halestrap AP. Protection by cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 1993; 25: 1461-9
79. 79. Massoudy P, Zahler S, Kupatt C, et al. Cardioprotection by cyclosporine A in experimental ischemia and reperfusion - evidence for a nitric oxide - dependent mechanism mediated by endothelin. J Mol Cell Cardiol 1997; 29: 535-44
80. 80. Mathieu P, Bendavid Y, Buluran J, et al. Cyclosporine A prevents ischemia-reperfusion myocardial dysfunction in the isolated rat heart. Ann Chir 1997; 51: 912-8
81. 81. Poston Jr RS, Billingham ME, Pollard J, et al. Effects of increased ICAM-1 on reperfusion injury and chronic graft vascular disease. Ann Thorac Surg 1997; 64: 1004-12
82. 82. Sakr M, Zetti G, Gavaler J, et al. Effect of renal ischemia on plasma levels of FK 506 in rats. Transplant Proc 1992; 24: 425-8
83. 83. Nalesnik MA, Lai HS, Murase N, et al. The effect of FK 506 on CyA on the Lewis rat renal ischemia model. Transplant Proc 1990; 22: 87-9
84. 84. Cacciarelli TV, Sumrani NB, Hong JH, et al. Influence of the timing of FK506 (tacrolimus) administration on recovery of renal function from warm ischemic injury in rats. ASAIO J 1994; 40: 964-7
85. 85. Cicalese L, Weber K, Lee RG. et al. Effect of FK506 on the mucosal perfusion of the rat intestinal allograft. Transplant Proc 1996; 28 (5): 2575
86. 86. Kubes P, Hunter J, Granger DN. Effects of cyclosporin A and FK506 on ischemia/reperfusion-induced neutrophil infiltration in the cat. Dig Dis Sci 1991; 36: 1469-72
87. 87. Puglisi RN, Strande L, Santos M, et al. The effect of cyclosporine in gut ischemic injury: a computerised morphometric and enzymatic analysis. J Pediatr Surg 1996; 31: 319-22
88. 88. Puglisi RN, Strande L, Santos M, et al. Beneficial effects of cyclosporine and rapamycin in small bowel ischemic injury. J Surg Res 1996; 65: 115-8
89. 89. Sakr M, Hassanein T, Gavaler J, et al. Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation - incidence, location, and severity in cyclosporine-and FK506-treated patients. Transplantation 1992; 53: 786-91
90. 90. Cetinkale O, Sengul R, Bilgic L, et al. Involvement of neutrophils in ischemic injury. I. Biochemical and histopathological investigation of the effect of FK506 on dorsal skin flaps in rats. Ann Plastic Surg 1997; 39: 505-15
91. 91. Cetinkale O, Bilgic L, Ayan F, et al. Neutrophil-mediated injury in ischemic skin flaps: amelioration of ischemic injury by cyclosporine in the rat. Ann Plastic Surg 1996; 37: 66-74
92. 92. Kucukcelebi A, Ozcan M. The beneficial effect of cyclosporin-A on the no-reflow phenomenon in rat skin island flaps. Br J Plastic Surg 1992; 45: 512-4
93. 93. Mason J. Pharmacology of cyclosporin (Sandimmune) VII. Pathophysiology and toxicology of cyclosporin in humans and animals. Pharmacol Rev 1989; 42 (3): 423-34
94. 94. Puschett JB, Greenberg A, Holley J, et al. The spectrum of cyclosporin nephrotoxicity. Am J Nephrol 1990; 10(4): 296-309
95. 95. Sonada T. Morphopathological findings of renal allografts under FK506 therapy: Japanese FK506 study group. Transplant Proc 1994; 26: 1933-6
96. 96. Giroux C, Scattom B. Ischemic stroke: treatment on the horizon. Eur Neurol 1996; 36 (2): 61-4
97. 97. Koroshetz WJ, Moskowitz MA. Emerging treatments for stroke in humans. Trends Pharmacol Sci 1996; 17 (6): 227-33
98. 98. Jean WC, Spellman SR, Nussbaum ES, et al. Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery 1998; 43: 1382-97
99. 99. Stoll G, Jander S, Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog Neurobiol 1998; 56: 149-71
100. 100. Wood PL. Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. Neurol Res 1995; 17: 242-48
101. 101. Arvin B, Neville LF, Barone FC, et al. The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 1996; 20: 445-52
102. 102. Kim JS. Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci 1996; 137: 69-78
103. 103. Sharma BK, Kumar K. Role of proinflammatory cytokines in cerebral ischemia: a review. Metab Brain Dis 1998; 13: 1-8
104. 104. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992; 23 (9): 1367-79
105. 105. Lehrmann E, Christensen T, Zimmer J, et al. Microglial and macrophage reactions mark progressive changes and define the penumbra in the rat neocortex and striatum after transient middle cerebral artery occlusion. J Comp Neurol 1997; 386: 461-76
106. 106. Fujimura T, Yang X, Soriano R, et al. Cellular surface molecular and cytokine gene expression in rat heart allografts under optimal doses of cyclosporine and FK 506. Transplant Proc 1998; 30: 1023-6
107. 107. Ohmori M, Kobayashi E, Harada K, et al. Do immunosuppressants directly affect neutrophils, resulting in protection of the liver against ischemia-reperfusion injury? Transplantation 1998; 66: 940-1
108. 108. Manev H, Favaron M, Fadda E, et al. Macrolide antibiotics protect neurons in culture against N-methyl-D-aspartate (NMDA) receptor mediated toxicity of glutamate. Brain Res 1993; 624 (1-2): 331-5
109. 109. Losa Garcia JE, Mateos Rodriguez F, Jimenez Lopez A, et al. Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages. Respir Med 1998; 92 (5): 722-8
110. 110. Lockhart BP, Cressey KC, Lepagnol JM. Suppression of nitric oxide formation by tyrosine kinase inhibitors in murine N9 microglia. Br J Pharmacol 1998; 123: 879-89
111. 111. Garcia JEL, Rodriguez FM, Lopez AJ, et al. Action of cyclosporin A on mononuclear phagocytes. J Invest Allergol Clin Immunol 1996; 6: 222-31
112. 112. Hortelano S, Lopez-Collazo E, Bosca L. Protective effect of cyclosporin A and FK506 from nitric oxide-dependent apoptosis in activated macrophages. Br J Pharmacol 1999; 126: 1139-46
113. 113. Matyszak MK. Inflammation in the CNS: balance between immunological privilege and immune responses. Prog Neurobiol 1998; 56: 19-35
114. 114. Buttini M, Appel K, Sauter A, et al. Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. Neurosci 1996; 71: 1-16
115. 115. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation and brain injury; role of tumour necrosis factor-α. Cerebrovasc Brain Metab Rev 1994; 6 (4): 341-60
116. 116. Fink K, Zhu J, Namura S, et al. Prolonged therapeutic window for ischemic brain damage caused by delayed caspase activation. J Cereb Blood Flow Metab 1998; 18: 1071-6
117. 117. Yamasaki Y, Itoyama Y, Kogure K. Involvement of cytokine production in the pathogenesis of transient cerebral ischaemic damage. Keio J Med 1996; 45: 225-9
118. 118. Yamasaki Y, Matsuura N, Shozuhara H, et al. Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995; 26: 676-81
119. 119. Endres M, Namura S, Shimizu-Sasamata M, et al. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cereb Blood Flow Metab 1998; 18: 238-47
120. 120. Sicsjo BK. Pathophysiology and treatment of focal cerebral ischemia. Pt II. Mechanisms of damage and treatment. J Neurosurg 1992; 77: 337-54
121. 121. Obrenovitch TP, Richards DA. Extracellular neurotransmitter changes in cerebral ischaemia. Cerebrovasc Brain Metab Rev 1995; 7: 1-54
122. 122. Rupalla K, Allegrini PR, Sauer D, et al. Time course of microglia activation and apoptosis in various brain regions after permanent focal cerebral ischemia in mice. Acta Neuropathol 1998; 96: 172-8
123. 123. Morioka T, Kalehua AN, Streit WJ. Characterization of microglial reaction after middle cerebral artery occlusion in rat brain. J Comp Neurol 1993; 327: 123-32
124. 124. Gebicke-Haerter PJ, Van Calker D, Norenberg W, et al. Molecular mechanisms of microglial activation. A. Implications for regeneration and neurodegenerative diseases. Neurochem Int 1996; 29: 1-12
125. 125. Giulian D, Vaca K, Corpuz M. Brain glia release factors with opposing actions upon neuronal survival. J Neurosci 1993; 13: 29-37
126. 126. Louw DF, Masada T, Sutherland GR. Ischemic neuronal injury is ameliorated by astrocyte activation. Can J Neurol Sci 1998; 25: S102-7
127. 127. Tacconi MT. Neuronal death: is there a role for astrocytes? Neurochem Res 1998; 23: 759-65
128. 2+ antiporter to ischemia and glial/neuronal death. Folia Pharmacol Jap 1998; 111 (1): 13-9
129. 129. Tsujikawa A, Ogura Y, Hiroshiba N, et al. Tacrolimus (FK506) attenuates leukocyte accumulation after transient retinal ischemia. Stroke 1998; 29: 1431-8
130. 130. Gonzalez-Amaro R, Diaz-Gonzalez F, Sanchez-Madrid F. Adhesion molecules in inflammatory diseases. Drugs 1998; 56: 977-88
131. 131. Karlsson H, Nassberger L. FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. Transplantation 1997; 64: 1217-20
132. 132. Chang HY, Takei K, Sydor AM, et al. Asymmetric retraction of growth cone filopodia following focal inactivation of calcincurin. Nature 1995; 376 (6542): 686-90
133. 133. Funauchi M, Haruta H, Tsumoto T. Effects of the inhibitor for calcium/calmodulin-dependent protein phosphatase, calcincurin, on induction of long-term potentiation in rat visual cortex. Neurosci Res 1994; 19 (3): 269-78
134. 134. Lyons WE, George EB, Dawson TM, et al. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci U S A 1994; 91 (8): 3191-5
135. 135. Moia LJMP, Matsui H, de Barros GAM, et al. Immunosuppressant and calcineurin inhibitors, cyclosporin A and FK506, reversibly inhibit eleptogenesis in amygdaloid kindled rat. Brain Res 1994; 648 (2): 337-41
136. 136. Torii N, Kamishita T, Otsu Y, et al. An inhibitor for calcineurin, FK506, blocks induction of long-term depression in rat visual cortex. Science 1994; 265: 674-6
137. 137. Dawson T, Steiner JP, Dawson VL, et al. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci U S A 1993; 90 (21): 9808-12
138. 2+ -dependent phosphatase. Nature 1994; 369 (6477): 235-9
139. 2+ flux. Cell 1995; 83: 463-72
140. 2+-activated phosphatase in the mammalian brain. Trends Neurosci 1989; 12 (3): 117-22
141. 141. Brillantes AB, Ondrias K, Scott A, et al. Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 1994; 77 (4): 513-23
142. 142. Cameron AM, Steiner JP, Sabalini DM, et al. Immunophilin FK506 binding protein associated with inositol 1,4,5-triphosphate receptor modulates calcium influx. Proc Natl Acad Sci U S A 1995; 92 (5): 1784-8
143. 143. Marriott J. Calcineurin regulates M-channel modal gating in sympathetic neurons. Neuron 1996; 16: 163-73
144. 144. Timerman AP, Ogunbumni E, Freund E, et al. The calcium release channel of the sarcoplasmic reticulum is modulated by FK506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1993; 268 (31): 22992-9
145. 145. Choi DW. Nitric oxide: foe or friend to the injured brain? Proc Natl Acad Sci U S A 1993; 90 (21): 9741-3
146. 146. Dawson DA. Nitric oxide and focal cerebral ischaemia: multiplicity of actions: multiplicity of actions and diverse outcome. Cerebrovasc Brain Metab Rev 1994; 6: 299-324
147. 147. Lipton SA, Choi YB, Pan ZH, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993; 364 (6438): 626-31
148. 148. Steiner JP, Dawson TM, Fotuhi M, et al. Immunophilin regulation of neurotransmitter release. Mol Med 1996; 2: 325-33
149. 149. Ankarcrona M, Dypbukt JM, Bonfoco E, et al. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron 1995; 15 (4): 961-73
150. 150. Nicolli A, Costantini P, Basso E, et al. Potential role of cyclosporin A-sensitive mitochondrial channels in ischemia-reperfusion injury. Transplant Proc 1995; 27: 2825-6
151. 151. Nieminen AL, Petrie TG, Lemasters JJ, et al. Cyclosporin a delays mitochondrial depolarization induced by N-methyl-D-aspartate in cortical neurons: evidence of the mitochondrial permeability transition. Neurosci 1996; 75: 993-7
152. 152. Schinder AF, Olson EC, Spitzer NC, et al. Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 1996; 16: 6125-33
153. 153. White RJ, Reynolds IJ. Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxic exposure. J Neurosci 1996; 16 (18): 568-97
154. 154. Duchen MR, McGuinness O, Brown LA, et al. On the involvement of a cyclosporin A sensitive mitochondrial pore in myocardial reperfusion injury. Cardiovasc Res 1993; 27: 1790-4
155. 155. Nakai A, Kuroda S, Kristian T, et al. The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat. Neurobiol Dis 1997; 4: 288-300
156. 156. Griffiths EJ, Halestrap AP. Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Biochem J 1991; 274: 611-4
157. 157. Nicolli A, Basso E, Petronilli V, et al. Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin-A-sensitive channel. J Biol Chem 1996; 271: 2185-92
158. 158. Murphy AN, Fiskum G, Beal MF. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J Cereb Blood Flow Metab 1999; 19 (3): 231-45
159. 159. Mancini M, Nicholson DW, Roy S, et al. The caspase-3 precursor has a cystolic and mitochondrial distribution: implications for apoptotic signalling. J Cell Biol 1998; 140: 1485-95
160. 160. Susin SA, Lorenzo HK, Zamzami N, et al. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J Exp Med 1999; 2: 381-94
161. 161. Andreyev AY, Fahy B, Fiskum G. Cytochrome c release from brain mitochondria is independent of the mitochondrial permeability transition. FEBS Lett 1998; 20: 373-6
162. 2+ ions. J Cell Biol 1998; 143: 217-24
163. 163. Bossy-Wetzel E, Newmeyer DD, Green DR. Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization. EMBO J 1998; 17: 37-49
164. 2+-sensitive cyclical mitochondrial depolarizations in cell culture. Biochem Biophys Acta 1999; 1410: 77-84
165. 165. Petronlilli V, Miotto G, Brini M, et al. Transient and long lasting-openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J 1999; 76: 725-34
166. 166. Jones PA, Henshall DC, Pollock JM, et al. Differing effects of the neuroprotective immunosuppressants FK506 and cyclosporin-A on local cerebral glucose utilisation in the rat [abstract]. Br Neurosci Assoc Abstr 1999; 15: 120
167. 167. Zini R, Simon N, Morin C, et al. Tacrolimus decreases in vitro oxidative phosphorylation of mitochondria from rat forebrain. Life Sci 1998; 63: 357-68
168. 168. Madsen KL, Yanchar NL, Sigalet DL, et al. FK506 increases permeability in rat intestine by inhibiting mitochondrial function. Gastroenterology 1995; 109: 107-14
169. 169. Nishino H, Fujimoto I, Shimano Y, et al. 3-Nitropropionic acid produces striatum selective lesions accompanied by iNOS expression. J Chem Neuroanal 1996; 10: 209-12
170. 170. Kitamura Y, Itano Y, Kubo T, et al. Suppressive effect of FK506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice. J Neuroimmunol 1994; 50: 221-4
171. 171. Seaton TA, Cooper JM, Schapira AH. Cyclosporin inhibition of apoptosis induced by mitochondrial complex I toxins. Brain Res 1998; 809: 12-7
172. 2+-loaded rat renal cortex mitochondria. Med Sci Res 1995; 23: 391-3
173. 173. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications. Br J Cancer 1972; 26 (4): 239-57
174. 174. Bonfoco E, Kraine D, Ankarcrona M, et al. Apoptosis and necrosis; two distinct events induced, respectively by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci U S A 1995; 92 (16): 7162-6
175. 175. Columhano A. Cell death: current difficulties in discriminating apoptosis from necrosis in the context of pathological processes in vivo. J Cell Biochem 1995; 58 (2): 181-90
176. 176. Wright SC, Zhong J, Larrick JW. Inhibition of apoptosis as a mechanism of tumour promotion. FASEB J 1994; 8 (9): 654-60
177. 177. Heron A, Pollard H, Dessi F, et al. Regional variability in DNA fragmentation after global ischemia evidenced by combined histological and gel electrophoresis observations in the rat brain. J Neurochem 1993; 61 (5): 1973-6
178. 178. Iwai T, Hara A, Niwa M, et al. Temporal profile of nuclear DNA fragmentation in situ in gerbil hippocampus following transient forebrain ischemia. Brain Res 1995; 671 (2): 305-8
179. 179. Li Y, Chopp M, Jiang N, et al. Temporal profile of in situ DNA fragmentation after transient middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1995; 15 (3): 389-97
180. 180. Li Y, Chopp M, Jiang N, et al. Induction of DNA fragmentation after 10 to 120 minutes of focal cerebral ischemia in rats. Stroke 1995; 26 (7): 1252-8
181. 181. Li Y, Sharov VG, Jiang N, et al. Ultrastructural and light microscopic evidence of apoptosis after middle cerebral artery occlusion in the rat. Am J Pathol 1995; 146: 1045-51
182. 182. Linnik MD, Zobrist RH, Hatfield MD. Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats. Stroke 1993; 24 (12): 2002-8; discussion 2008-9
183. 183. Okamoto M, Matsumoto M, Ohtsuki T, et al. Internucleosomal DNA cleavage involved in ischemia-induced neuronal death. Biochem Biophys Res Comm 1993; 196: 1356-62
184. 184. Tominaga T, Kure S, Narisawa K, et al. Endonuclease activation following focal ischemic injury in the rat brain. Brain Res 1993; 60 (1): 821-6
185. 185. Li Y, Chopp M, Jiang N, et al. In situ detection of DNA fragmentation after focal cerebral ischemia in mice. Mol Brain Res 1995; 28 (1): 164-8
186. 186. Linnik MD, Miller JA, Sprinle-Cavallo J, et al. Apoptotic fragmentation in the rat cerebral cortex induced by permanent middle cerebral artery occlusion. Mol Brain Res 1995; 32 (1): 116-24
187. 187. Sharkey J, Kelly JS, Butcher SP. Inflammatory responses to cerebral ischemia. In: Ter Horst GJ, Korf J, editors. Clinical pharmacology of cerebral ischaemia. Totowa (NJ): Humana Press, Inc., 1997: 235-63
188. 188. MacManus JP, Linnik MD. Gene expression induced by cerebral ischemia: an apoptotic perspective. J Cereb Blood Flow Metab 1997; 17: 815-32
189. 189. Matsushita K, Matsuyama T, Kitagawa K, et al. Alterations of Bcl-2 family proteins precede cytoskeletal proteolysis in the penumbra, but not in infarct centres following focal cerebral ischemia in mice. Neuroscience 1998; 83 (2): 439-48
190. 190. Shibasaki F, Kondo E, Akagi T, et al. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature 1997; 386: 728-31
191. 191. Gross A, Jockel J, Wei MC, et al. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17: 3878-85
192. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999; 284: 339-43
193. 193. Herr I, Martin-Villalba A, Kurz E, et al FK506 prevents stroke-induced generation of ceramide and apoptosis signalling. Brain Res 1999; 826: 210-9
194. 194. Yardin C, Terro F, Lesort M, et al. FK506 antagonises apoptosis and C-jun protein expression in neuronal cultures. Neuro-report 1998; 22: 2077-80
195. 195. Montague JW, Hughes Jr FM, Cidlowski JA. Native recombinant cyclophilins A, B and C degrade DNA independently of polypeptide cis-trans-isomerase activity. Potential roles of cyclophilins in apoptosis. J Biol Chem 1997; 272: 6677-84
196. 196. Nagata K, Sasaki T, Iwama J, et al. Failure of FK-506, a new immunosuppressant, to prevent cerebral vasospasm in a canine two-hemorrhage model. J Neurosurg 1993; 79: 710-5
197. 197. Nishizawa S, Peterson JW, Shimoyama I, et al. Therapeutic effect of a new immunosuppressant, FK-506, on vasospasm after subarachnoid hemorrhage. Neurosurg 1993; 32: 986-92
198. 198. Peterson JW, Nishizawa S, Hackett JD, et al. Cyclosporine A reduces cerebral vasospasm after subarachnoid hemorrhage in dogs. Stroke 1990; 21: 133-7
199. 199. Ryba M, Iwanska K, Walski M, et al. Immunomodulators interfere with angiopathy but not vasospasm after subarachnoid haemorrhage in rabbits. Acta Neurochir 1991; 108: 81-4
200. 200. Handa Y, Hayashi M, Takeuchi H, et al. Effect of cyclosporine on the development of cerebral vasospasm in a primate model. Neurosurg 1991; 28: 380-6
201. 201. Yanamoto H, Kikuchi H, Okamoto S. Effects of protease inhibitor and immunosuppressant on cerebral vasospasm after subarachnoid hemorrhage in rabbits. Surg Neurol 1994; 42: 382-7
202. 202. Manno EM, Gress DR, Ogilvy CS, et al. The safety and efficacy of cyclosporine A in the prevention of vasospasm in patients with Fisher Grade 3 subarachnoid hemorrhages: a pilot study. Neurosurg 1997; 40: 289-93
203. 203. Ryba M, Pastuszko M, Dziewiecki C, et al. A strategy for analyzing multiple parameters with application to aneurysmal SAH patients all of them clipped but treated with and without cyclosporine. Acta Neurochir 1993; 122: 194-9
204. 204. Beal MF, Hyman BT, Koroshetz WJ. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993; 16 (4): 125-31
205. 205. Good PF, Werner P, Hsu A, et al. Evidence fov neuronal oxidative damage in Alzheimer's disease. Am J Pathol 1996; 149: 21-8
206. 206. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci 1993; 16: 439-44
207. 207. Jenkins BG, Brouillet E, Chen YCI, et al. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 1996; 16: 450-61